



**NEOGEN**  
CHEMICALS LTD.

May 14, 2022

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 <b>Scrip Code No: 542665</b>	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 <b>Company Symbol: NEOGEN</b>
--	---

**Sub: Outcome of Board Meeting held on Saturday, May 14, 2022.**

Dear Sir/Madam,

With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, May 14, 2022, inter alia considered and approved the following:

1. Approved the Audited Financial Results (Standalone and Consolidated) of the Company along with the Audit Reports for the Quarter and Financial Year ended March 31, 2022, pursuant to Regulation 33 of the Listing Regulations, which has been duly reviewed and recommended by the Audit Committee; Pursuant to Regulation 33(3) (d) of the Listing Regulations, we would like to declare that the Statutory Auditors of the Company M/s JMT & Associates, Chartered Accountants (FRN: 104167W) have issued the Auditors Report on Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2022 with un-modified opinion and a declaration to that effect is enclosed.
2. Recommended a final dividend of Rs. 2.75 per Equity Share for the Financial Year 2021-22, subject to approval of shareholders at the ensuing General Meeting of the Company.
3. Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation/ Variation in utilization of funds ("Statement") as at March 31, 2022, which has been duly reviewed by the Audit Committee.
4. Considered and approved an estimated capex of upto Rs. 150 crores at Dahej SEZ Plant for:
  - a) Increasing manufacturing capacity of specialty organic chemicals;
  - b) Increasing the capacity for manufacturing of inorganic salts;
  - c) Setting up capacity for manufacturing Specialty Lithium Salts for Electrolyte used in Lithium-Ion batteries advance chemistry cells;
  - d) Dahej site development.



*[Handwritten Signature]*

**Registered Office :** 1002, Dev Corpora, Cadbury Junction,  
Eastern Express Highway, Thane (W) 400 601, India.  
**CIN No.** L24200MH1989PLC050919

**E :** sales@neogenchem.com  
**W :** www.neogenchem.com

**T :** +91 22 2549 7300  
**F :** +91 22 2549 7399



**NEOGEN**  
CHEMICALS LTD.

The information contained in this outcome is also available on the Company's website [www.neogenchem.com](http://www.neogenchem.com), on the website of the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and BSE Limited ([www.bseindia.com](http://www.bseindia.com)).

The Board Meeting commenced at 3.30 p.m. and concluded at 10.50 p.m.

Kindly take the same on your record.

Thanking you,  
Yours faithfully,

**For Neogen Chemicals Limited**

**Unnati Kanani**

**Company Secretary and Compliance Officer**

**Membership No: ACS 35131**



- Encl:** 1. Audited Standalone and Consolidated Financial Results of the Company along with Audit Report for the quarter and Financial Year ended March 31, 2022.  
2. Declaration pursuant to Regulation 32 of Listing Regulations  
3. Declaration pursuant to Regulation 33 of Listing Regulations.



**Independent Auditor's Report on the audit of the annual financial results of the Company with the last quarter financial results being balancing figures Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors  
Neogen Chemicals Limited

**Report on the audit of the Financial Results**

**Opinion**

We have audited the accompanying Statement of Quarterly and Annual Financial Results of **Neogen Chemicals Limited** ("the Company") for the quarter and year ended 31/03/2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. is presented in accordance with the requirement of the Listing Regulations in this regards; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive profit and other financial information of the Company for the quarter and year ended March 31, 2022

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



## **Responsibilities of Management and Those Charged with Governance for the Financial Results**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the net profit and other comprehensive loss and other financial information of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act read with relevant rules issued thereunder and in line with the requirement of the Listing Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the company are also responsible for overseeing the financial reporting process of the Company.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.







**Statement of Standalone Audited Financial Results for the Quarter and year ended March 31, 2022**

(Rs. in Cr)						
Sr. No.	Particulars	Standalone				
		For the Quarter Ended			For the year ended	
		31-March-22 Audited	31- Dec- 21 Unaudited	31-March-21 Audited	31 -March-22 Audited	31- March 21 Audited
<b>I</b>	<b>Income</b>					
	(a) Revenue from operations	156.80	132.64	92.70	487.25	336.41
	(b) Other income	0.96	0.04	0.10	1.34	0.63
	<b>Total Income (net)</b>	<b>157.76</b>	<b>132.68</b>	<b>92.80</b>	<b>488.59</b>	<b>337.04</b>
<b>II</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	108.34	94.79	52.28	343.77	180.76
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(18.13)	(20.70)	0.14	(68.80)	16.87
	(c) Employee benefits expense	8.91	8.38	4.76	31.50	20.07
	(d) Finance costs	5.02	6.36	3.50	19.08	13.77
	(e) Depreciation and Amortization Expense	3.79	3.72	1.86	11.69	6.90
	(f) Other Expenses	31.06	26.36	17.00	94.19	54.35
	<b>Total Expenses</b>	<b>138.99</b>	<b>118.91</b>	<b>79.54</b>	<b>431.43</b>	<b>292.72</b>
<b>III</b>	<b>Profit/(loss) before taxes (I-II)</b>	<b>18.77</b>	<b>13.77</b>	<b>13.26</b>	<b>57.16</b>	<b>44.32</b>
<b>IV</b>	<b>Income Tax</b>					
	1. Current Tax	2.83	2.74	3.33	9.87	10.37
	2. Deferred Tax	0.27	0.55	0.58	2.57	2.51
<b>V</b>	<b>Profit for the period (III-IV)</b>	<b>15.67</b>	<b>10.48</b>	<b>9.35</b>	<b>44.72</b>	<b>31.44</b>
<b>VI</b>	<b>Other comprehensive income</b>					
	i) Items that will not be reclassified to profit or loss	(0.42)	0.01	(0.02)	(0.40)	0.08
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.12	(0.00)	0.00	0.12	(0.03)
	<b>Total Other comprehensive (expense)/income, net of tax</b>	<b>(0.30)</b>	<b>0.01</b>	<b>(0.02)</b>	<b>(0.28)</b>	<b>0.05</b>
<b>VII</b>	<b>Total comprehensive income for the period (V + VI)</b>	<b>15.37</b>	<b>10.49</b>	<b>9.33</b>	<b>44.44</b>	<b>31.49</b>
<b>VIII</b>	<b>Paid up equity Share Capital (Face Value per share of Rs. 10/- each)</b>	24.94	23.33	23.33	24.94	23.33
<b>IX</b>	<b>Other Equity</b>				414.38	159.79
<b>X</b>	<b>Weighted Average Earnings Per Share Rs.</b>					
	Basic & Diluted (*Not Annualized)	5.50*	4.50*	4.00*	18.74	13.50

For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Place : Thane , India  
Date : 14th May ,2022

Dr. Harin Kanani  
Managing Director  
DIN : 05136947



**Statement of Standalone Audited Balance Sheet as at March 31, 2022**

(₹ in Cr)

	Standalone	
	Audited	Audited
	As at 31/03/2022	As at 31/03/2021
<b>ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, plant and equipment	281.78	121.53
(b) Right to Use Assets	3.19	4.85
(c) Capital work-in-progress	10.62	114.65
(d) Intangible assets	0.16	0.33
(e) Financial assets		
(i) Investments	0.45	0.45
(ii) Loans	8.48	7.34
(f) Other non-current assets	1.60	2.35
<b>Total Non-current Assets</b>	<b>306.28</b>	<b>251.50</b>
<b>(2) Current Assets</b>		
(a) Inventories	194.59	114.03
(b) Financial assets		
(i) Investments	80.76	-
(ii) Trade receivables	109.50	78.55
(iii) Cash and cash equivalents	32.80	0.51
(iv) Bank balances other than (ii) above	12.42	0.70
(v) Loans	0.60	0.41
(vi) Other current financial assets	40.47	24.96
(c) Other current assets	21.92	21.41
<b>Total Current Assets</b>	<b>493.06</b>	<b>240.57</b>
<b>TOTAL ASSETS</b>	<b>799.34</b>	<b>492.07</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
(a) Equity share capital	24.94	23.33
(b) Other equity	414.38	159.79
<b>Total Equity</b>	<b>439.32</b>	<b>183.12</b>
<b>(2) Non-current liabilities</b>		
(a) Financial liabilities		
- Borrowings	121.52	116.10
- Lease Liabilities	1.95	1.72
- Other Non-current Financial Liabilities	3.80	2.00
(b) Long Term Provisions	4.04	3.03
(c) Deferred tax liabilities (net)	10.61	8.16
<b>Total Non-current Liabilities</b>	<b>141.92</b>	<b>131.01</b>
<b>(3) Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	76.20	85.79
(ii) Lease Liabilities	2.07	4.02
(iii) Trade payables		
(a) Total outstanding dues of Micro-enterprises and small enterprises	6.15	0.71
(b) Total outstanding dues of other than micro-enterprises and small enterprises	92.73	65.37
(iv) Other financial liabilities	36.88	19.13
(b) Other current liabilities	2.20	1.80
(c) Short-term provisions	1.87	1.12
<b>Total Current liabilities</b>	<b>218.10</b>	<b>177.94</b>
<b>Total Liabilities</b>	<b>360.02</b>	<b>308.95</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>799.34</b>	<b>492.07</b>

For and on behalf of Board of Directors of  
Neogen Chemicals Limited

Place : Thane , India  
Date : 14th May ,2022

Dr. Harin Kanani  
Managing Director  
DIN : 05136947



**Statement of Standalone Audited Cash Flow for the year ended March 31, 2022**

(Rs. In Cr)

Particulars	Standalone	
	For the Year Ended	For the Year Ended
	<b>31 March 2022</b>	<b>31 March 2021</b>
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit/(loss) before extra - ordinary Items & tax	57.16	44.32
Adjustments for:		
Finance costs recognized in profit or loss	19.08	13.77
Investment income recognized in profit or loss	(1.29)	(0.51)
Provision for non cash items	0.21	0.05
Loss on disposal of property, plant and equipment	(0.11)	-
Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	1.49	(0.80)
Depreciation and amortization of non-current assets	11.69	6.90
Net foreign exchange (gain)/loss	(7.06)	(6.66)
<b>Operating profit before working capital changes Movement in working capital</b>	<b>81.17</b>	<b>57.07</b>
Increase in trade and other receivables	(31.16)	(3.37)
(Increase)/decrease in inventories	(80.56)	15.84
(Increase)/decrease in other current and non-current financial assets	(16.41)	(21.62)
(Increase) /Decrease in trade and other payables	39.86	36.89
Increase/(decrease) in provisions	0.27	1.21
(Decrease)/increase in other liabilities	17.83	7.64
<b>Cash flow from/ (utilized in) operating activities post working capital changes</b>	<b>(70.17)</b>	<b>36.59</b>
Income tax (paid)/Refunds (net)	(9.80)	(10.37)
<b>Net cash flow from/(utilized in) operating activities (A)</b>	<b>1.20</b>	<b>83.29</b>
<b>B) CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Payments to acquire financial assets	(80.76)	
Interest received		
- BANK & OTHERS	1.11	0.13
- Other Income	0.18	0.38
Amounts advanced to related parties	(0.19)	0.23
Payments for property, plant and equipment	(170.28)	(23.06)
Capital WIP	104.04	(111.95)
Proceeds from disposal of property, plant and equipment	0.11	-
Payments for intangible assets	0.17	(0.02)
<b>Net cash flow from / (utilized) in investing activities (B)</b>	<b>(145.62)</b>	<b>(134.29)</b>
<b>C) CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity instruments of the Company	225.00	-
Payment for share issue costs	(7.31)	-
Proceeds from borrowings	38.88	97.84
Repayment of borrowings	(43.04)	(28.24)
Finance Cost	(19.08)	(13.77)
Prior Period & other items / Taxes	(0.77)	(0.43)
Dividends paid to shareholders of the Company	(5.25)	(4.67)
<b>Net cash flow from/(utilized in) financing activities (C)</b>	<b>188.43</b>	<b>50.73</b>
<b>Net Increase/ (Decrease) in cash and Cash equivalents (A+B+C)</b>	<b>44.01</b>	<b>(0.27)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>1.21</b>	<b>1.48</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>45.22</b>	<b>1.21</b>
<b>Reconciliation of cash and cash equivalents as per the cash flow Statement</b>		
Cash and cash equivalents	32.80	0.51
Bank Current Balances and Deposit	12.42	0.70
	<b>45.22</b>	<b>1.21</b>

The above cash flow statement has been prepared under the indirect method as set out in Indian Accounting standard 7 "Statement of Cash Flows"

**For and on behalf of Board of Directors of  
Neogen Chemicals Limited**

Place : Thane , India  
Date : 14th May ,2022

**Dr. Harin Kanani**  
Managing Director  
DIN : 05136947

Notes :

1. The above audited financial results of the Company for the quarter and financial year ended March 31, 2022 have been prepared in accordance with the principles as laid under the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and were reviewed by the Statutory Auditor, recommended by the Audit Committee and was approved by the Board of Directors at their meeting held on May 14, 2022.
2. The impact of Covid-19 on the operations and financials of the Company depends on future developments that are uncertain and un-predictable. The company is continuously monitoring the economic conditions and has outlined certain measures to combat the pandemic situation and to minimize the impact on its business.
3. The Board of Directors of the company at its meeting held on May 14, 2022, has recommended a final dividend of Rs. 2.75 per equity share on the paid-up equity share capital of the company for the F.Y. 2021-22.
4. The Board of Directors at its meeting held on 8<sup>th</sup> December, 2021, inter alia approved the issue and offer of 16,04,710 equity shares on preferential basis for cash consideration. Subsequently the shareholders of the Company at its Extra Ordinary General meeting held on 31<sup>st</sup> December, 2021 has approved issue and offer of 16,04,710 shares of face value of Rs. 10 each on preferential basis at an issue price of Rs. 1,402.12 per Equity Share (including a premium of Rs. 1,392.12 per Equity Share) aggregating up to Rs. 2,24,99,95,985.20 to the identified investors. The allotment of the said equity shares of the Company on a preferential basis was done on 6<sup>th</sup> January, 2022. The Equity shares were listed at BSE Limited and National Stock Exchange of India Limited.
5. The details of utilization of above proceeds raised by way of issue of Equity shares on preferential Issue basis are as follows:

(Rs. In crore)

Sr. no	Particulars	Proposed Allocation of Fund	Utilized as on 31.03.2022*	Unutilized amount as at 31.03.2022
1	funding the long-term growth and expansion of its existing businesses;	225.00	148.82	76.18
2	financing capital expenditure & working capital requirements;			
3	pre-payment and / or repayment of working capital loans;			
4	General corporate purpose;			
5	Any other matters as may be permissible under applicable law(s).			
	<b>Total Amount</b>	<b>225.00</b>	<b>148.82</b>	<b>76.18</b>

\*Funds utilised includes Rs. 7.3 crore on account of issue related expenses

6. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
7. The figures for the quarter ended March 31, 2022 and March 31, 2021, are arrived at as difference between the audited figures in respect of the full financial year and the unaudited figures up to nine months of the relevant financial year which were subjected to limited review.
8. The company is in the business of manufacturing of specialty chemicals and accordingly has one reportable business segment.

9. For more details on results, visit investor relations section of the Company's website at [www.neogenchem.com](http://www.neogenchem.com) and financial result under corporates section of Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

---

**For and on behalf of the Board of Directors of  
Neogen Chemicals Limited**

**Place: Thane, India  
Date: 14<sup>th</sup> May, 2022**

**Dr. Harin Kanani  
Managing Director  
DIN: 05136947**



**Independent Auditor's Report on the audit of the annual financial results of the Company with the last quarter financial results being balancing figures Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors  
Neogen Chemicals Limited

**Report on the audit of the Consolidated Financial Results**

**Opinion**

We have audited the accompanying Statement of Quarterly and Annual Consolidated Financial Results of **Neogen Chemicals Limited** ("the Company") and its joint venture (the Company and its joint venture together referred to as "the Group") and its share of the net profit after tax and total comprehensive income accounted under equity method of accounting of its Joint Venture for the quarter and year ended 31/03/2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. Include the results of the following entity:  
**Joint Venture**  
Dhara Finechem Industries (Registered Partnership Firm)
- ii. are the present in accordance with the requirement of the Listing Regulations in this regards and;
- iii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit and other financial information of the Company for the quarter and year ended March 31, 2022



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Company and its joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Results**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the net profit and other comprehensive profit and other financial information of the Company including its joint venture in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act read with relevant rules issued thereunder and in line with the requirement of the Listing Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company including its Joint Venture and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the respective Board of Directors of the Company and its joint ventures are responsible for assessing the ability of the Company and its joint ventures to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The respective Board of Directors of the company and its joint ventures are also responsible for overseeing the financial reporting process of the Company and its joint venture.



## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the



underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Company of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Company and its joint venture included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular No. CTR/CFD/CMD 1/44/2019 dated March 29, 2019 issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

### Other Matter

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations

UDIN: 22039910AIZVMG1000



For **JMT & Associates**  
Chartered Accountants  
FRN No. 104167W

Jayesh  
Jashvantlal  
Shah

Digitally signed by Jayesh Jashvantlal Shah  
DN: c=IN, o=Personel, ou=7311,  
email=jshah@jmt.com, cn=Jayesh Jashvantlal Shah  
2.5.4.20=00148775823d893bc44197261485  
908a407ca7260d431438f90c0a49f23a,  
serialNumber=400005, cn=Jayesh Jashvantlal  
Shah, email=jshah@jmt.com, cn=Jayesh Jashvantlal  
Shah, cn=Jayesh Jashvantlal Shah,  
date=2022.05.13 18:18:14 +05'30'

Jayesh Shah  
Partner

Membership No. 039910

Mumbai, May 14, 2022



**Statement of Consolidated Audited Financial Results for the Quarter and year ended March 31, 2022**

(Rs. in Cr)						
Sr. No.	Particulars	Consolidated				
		For the Quarter Ended			For the year ended	
		31-March-22 Audited	31- Dec- 21 Unaudited	31-March-21 Audited	31 -March-2022 Audited	31- March 2021 Audited
<b>I</b>	<b>Income</b>					
	(a) Revenue from operations	156.80	132.64	92.70	487.25	336.41
	(b) Other income	0.85	0.03	0.02	1.07	0.14
	<b>Total Income (net)</b>	<b>157.65</b>	<b>132.67</b>	<b>92.72</b>	<b>488.32</b>	<b>336.55</b>
<b>II</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	108.34	94.79	52.28	343.77	180.76
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(18.13)	(20.70)	0.14	(68.80)	16.87
	(c) Employee benefits expense	8.91	8.38	4.76	31.50	20.07
	(d) Finance costs	5.02	6.36	3.50	19.08	13.77
	(e) Depreciation and Amortization Expense	3.79	3.72	1.86	11.69	6.90
	(f) Other Expenses	31.06	26.36	17.00	94.19	54.35
	<b>Total Expenses</b>	<b>138.99</b>	<b>118.91</b>	<b>79.54</b>	<b>431.43</b>	<b>292.72</b>
<b>III</b>	Share of profit from Joint Venture	0.08	(0.01)	0.06	0.18	0.38
<b>IV</b>	<b>Profit/(loss) before taxes (I - II + III)</b>	<b>18.74</b>	<b>13.75</b>	<b>13.24</b>	<b>57.07</b>	<b>44.21</b>
<b>V</b>	<b>Income Tax</b>					
	1. Current Tax	2.83	2.74	3.33	9.87	10.37
	2. Deferred Tax	0.27	0.55	0.58	2.57	2.51
<b>VI</b>	<b>Profit for the period (IV-V)</b>	<b>15.64</b>	<b>10.46</b>	<b>9.33</b>	<b>44.63</b>	<b>31.33</b>
<b>VII</b>	<b>Other comprehensive income</b>					
	i) Items that will not be reclassified to profit or loss	(0.42)	0.01	(0.02)	(0.40)	0.08
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.12	(0.00)	0.00	0.12	(0.03)
	<b>Total Other comprehensive (expense)/income, net of tax</b>	<b>(0.30)</b>	<b>0.01</b>	<b>(0.02)</b>	<b>(0.28)</b>	<b>0.05</b>
<b>VIII</b>	<b>Total comprehensive income for the period (VI+VII)</b>	<b>15.34</b>	<b>10.47</b>	<b>9.31</b>	<b>44.35</b>	<b>31.38</b>
<b>IX</b>	Paid up equity Share Capital (Face Value per share of Rs. 10 each)	24.94	23.33	23.33	24.94	23.33
<b>X</b>	Other Equity				414.30	159.68
<b>XI</b>	Weighted Average Earning Per Equity Share Rs.					
	(a) Basic & Diluted (*Not Annualized)	5.50*	4.49*	3.99*	18.70	13.45

For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Place : Thane , India  
Date : 14th May ,2022

Dr. Harin Kanani  
Managing Director  
DIN : 05136947



**Statement of Consolidated Audited Balance Sheet as at March 31, 2022**

(₹ in Cr)

	Consolidated	
	Audited	Audited
	As at 31/03/2022	As at 31/03/2021
<b>ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, plant and equipment	281.78	121.53
(b) Right to Use Assets	3.19	4.85
(c) Capital work-in-progress	10.62	114.65
(d) Intangible assets	0.16	0.33
(e) Financial assets		
(i) Investments	0.97	0.75
(ii) Other financial assets	8.48	7.34
(f) Other non-current assets	1.60	2.35
<b>Total Non-current Assets</b>	<b>306.80</b>	<b>251.80</b>
<b>(2) Current Assets</b>		
(a) Inventories	194.59	114.03
(b) Financial assets		
(i) Investments	80.76	-
(ii) Trade receivables	109.50	78.55
(iii) Cash and cash equivalents	32.80	0.51
(iv) Bank balances other than (ii) above	12.42	0.70
(v) Other current financial assets	40.47	24.96
(c) Other current assets	21.92	21.41
<b>Total Current Assets</b>	<b>492.46</b>	<b>240.16</b>
<b>TOTAL ASSETS</b>	<b>799.26</b>	<b>491.96</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
(a) Equity share capital	24.94	23.33
(b) Other equity	414.30	159.68
<b>Total Equity</b>	<b>439.24</b>	<b>183.01</b>
<b>(2) Non-current liabilities</b>		
(a) Financial liabilities		
- Borrowings	121.52	116.10
- Lease Liabilities	1.95	1.72
- Other Non-current Financial Liabilities	3.80	2.00
(b) Long Term Provisions	4.04	3.03
(c) Deferred tax liabilities (net)	10.61	8.16
<b>Total Non-current Liabilities</b>	<b>141.92</b>	<b>131.01</b>
<b>(3) Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	76.20	85.79
(ii) Lease Liabilities	2.07	4.02
(iii) Trade payables		
(a) Total outstanding dues of Micro-enterprises and small enterprises	6.15	3.39
(b) Total outstanding dues of other than micro-enterprises and small enterprises	92.73	62.69
(iv) Other financial liabilities	36.88	19.13
(b) Other current liabilities	2.20	1.80
(c) Short-term provisions	1.87	1.12
<b>Total Current liabilities</b>	<b>218.10</b>	<b>177.94</b>
<b>Total Liabilities</b>	<b>360.02</b>	<b>308.95</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>799.26</b>	<b>491.96</b>

For and on behalf of Board of Directors of  
Neogen Chemicals Limited

Place : Thane , India  
Date : 14th May ,2022

Dr. Harin Kanani  
Managing Director  
DIN: 05136947



**Statement of Consolidated Audited Cash Flow for the year ended March 31, 2022**

(Rs. In Cr)

Particulars	Consolidated	
	For the Year Ended 31 March 2022	For the Year Ended 31 March 2021
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit/(loss) before extra - ordinary Items & tax	57.07	44.21
Adjustments for:		
Finance costs recognized in profit or loss	19.08	13.77
Investment income recognized in profit or loss	(1.08)	(0.13)
Provision for non cash items	0.21	0.05
Profit/ (Loss) on disposal of property, plant and equipment	(0.11)	-
Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	1.49	(0.80)
Depreciation and amortization of non-current assets	11.69	6.90
Net foreign exchange (gain)/loss	(7.06)	(6.65)
<b>Operating profit before working capital changes Movement in working capital</b>	<b>81.29</b>	<b>57.35</b>
(Increase)/ Decrease in trade and other receivables	(31.16)	(3.37)
(Increase)/decrease in inventories	(80.56)	15.84
(Increase)/decrease in other current and non-current financial assets	(16.32)	(21.62)
Increase /(decrease) in trade and other payables	39.86	36.89
Increase/(decrease) in other liabilities	18.10	8.85
<b>Cash flow from/(utilized in) operating activities post working capital changes</b>	<b>(70.08)</b>	<b>36.59</b>
Income tax (paid)/Refunds (net)	(9.80)	(10.37)
<b>Net cash flow from/(utilized in) operating activities (A)</b>	<b>1.41</b>	<b>83.57</b>
<b>B) CASH FLOWS FROM INVESTING ACTIVITIES</b>		
- Payments to acquire financial assets	(80.76)	-
- Interest received from banks and others	0.94	0.13
- Other Income	0.14	-
- Amounts advanced to related parties	(0.19)	0.34
Payments for property, plant and equipment	(170.28)	(23.06)
Capital WIP	104.04	(111.96)
Proceeds from disposal of property, plant and equipment	0.11	-
Payments for intangible assets	0.17	(0.02)
<b>Net cash flow from /(utilized) in investing activities (B)</b>	<b>(145.83)</b>	<b>(134.57)</b>
<b>C) CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity instruments of the Company	225.00	
Payment for share issue costs	(7.31)	
Proceeds from borrowings	38.88	97.84
Repayment of borrowings	(43.04)	(28.24)
Finance Cost	(19.08)	(13.77)
Prior Period & other items / Taxes	(0.77)	(0.43)
Dividends paid to shareholders of the Company	(5.25)	(4.67)
<b>Net cash flow from/(utilized in) financing activities (C)</b>	<b>188.43</b>	<b>50.73</b>
<b>Net Increase/ (Decrease) in cash and Cash equivalents (A+B+C)</b>	<b>44.01</b>	<b>(0.27)</b>
Cash and cash equivalents at the beginning of the year	1.21	1.48
<b>Cash and cash equivalents at the end of the year</b>	<b>45.22</b>	<b>1.21</b>
<b>Reconciliation of cash and cash equivalents as per the cash flow Statement</b>		
Cash and cash equivalent	32.80	0.51
Bank Current Balances and Deposit	12.42	0.70
	<b>45.22</b>	<b>1.21</b>

The above cash flow statement has been prepared under the indirect method as set out in Indian Accounting standard 7 "Statement of Cash Flows"

**For and on behalf of Board of Directors of  
Neogen Chemicals Limited**

Place : Thane , India  
Date : 14th May ,2022

**Dr. Harin Kanani**  
Managing Director  
DIN : 05136947

Notes :

1. The above audited financial results of the Company for the quarter and financial year ended March 31, 2022 have been prepared in accordance with the principles as laid under the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and were reviewed by the Statutory Auditor, recommended by the Audit Committee and was approved by the Board of Directors at their meeting held on May 14, 2022.
2. The impact of Covid-19 on the operations and financials of the Company depends on future developments that are uncertain and un-predictable. The company is continuously monitoring the economic conditions and has outlined certain measures to combat the pandemic situation and to minimize the impact on its business.
3. The Board of Directors of the company at its meeting held on May 14, 2022, has recommended a final dividend of Rs. 2.75 per equity share on the paid-up equity share capital of the company for the F.Y. 2021-22.
4. The Board of Directors at its meeting held on 8<sup>th</sup> December, 2021, inter alia approved the issue and offer of 16,04,710 equity shares on preferential basis for cash consideration. Subsequently the shareholders of the Company at its Extra Ordinary General meeting held on 31<sup>st</sup> December, 2021 has approved issue and offer of 16,04,710 shares of face value of Rs. 10 each on preferential basis at an issue price of Rs. 1,402.12 per Equity Share (including a premium of Rs. 1,392.12 per Equity Share) aggregating up to Rs. 2,24,99,95,985.20 to the identified investors. The allotment of the said equity shares of the Company on a preferential basis was done on 6<sup>th</sup> January, 2022. The Equity shares were listed at BSE Limited and National Stock Exchange of India Limited.
5. The details of utilization of above proceeds raised by way of issue of Equity shares on preferential Issue basis are as follows:

(Rs. In crore)

Sr. no	Particulars	Proposed Allocation of Fund	Utilized as on 31.03.2022*	Unutilized amount as at 31.03.2022
1	funding the long-term growth and expansion of its existing businesses;	225.00	148.82	76.18
2	financing capital expenditure & working capital requirements;			
3	pre-payment and / or repayment of working capital loans;			
4	General corporate purpose;			
5	Any other matters as may be permissible under applicable law(s).			
	<b>Total Amount</b>	<b>225.00</b>	<b>148.82</b>	<b>76.18</b>

\*Funds utilised includes Rs. 7.3 crore on account of issue related expenses

6. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
7. The figures for the quarter ended March 31, 2022 and March 31, 2021, are arrived at as difference between the audited figures in respect of the full financial year and the unaudited figures up to nine months of the relevant financial year which were subjected to limited review.
8. The company is in the business of manufacturing of specialty chemicals and accordingly has one reportable business segment.

9. For more details on results, visit investor relations section of the Company's website at [www.neogenchem.com](http://www.neogenchem.com) and financial result under corporates section of Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

---

**For and on behalf of the Board of Directors of  
Neogen Chemicals Limited**

**Place: Thane, India  
Date: 14<sup>th</sup> May, 2022**

**Dr. Harin Kanani  
Managing Director  
DIN: 05136947**



**NEOGEN**  
CHEMICALS LTD.

May 14, 2022

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
---	--

**Sub: Compliance pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ("Listing Regulations")**

Dear Sir/Madam,

With reference to the captioned subject, please note that the Board of Directors at its meeting held on Saturday, May 14, 2022, approved Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022.

Further as required in terms of Regulation 33(3) (d) of the Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company M/s JMT & Associates, Chartered Accountants (FRN: 104167W) have issued the Auditors Report on Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022 with un-modified opinion.

The same may please be taken on record.

Thanking you,  
Yours faithfully,  
For Neogen Chemicals Limited

Ketan Vyas  
Chief financial Officer





Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation.

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Neogen Chemicals Limited
Mode of Fund Raising	Preferential Issue of Equity Shares
Date of Raising Funds	06-01-2022
Amount Raised (Rs. In crores)	225 crores
Report filed for Quarter ended	31-03-2022
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation, in the following table	See table below

(Amount in Crores)


Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 31.03.2022*	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
a) funding the long term growth and expansion of its existing businesses;	Not Applicable	225	Not Applicable	148.82	Nil	Nil
b) financing capital expenditure & working capital requirements;						
c) pre-payment and / or repayment of loans;						
d) General corporate purpose; and / or						
e) Any other matters as may be permissible under applicable law(s).						
		225		148.82		

**Deviation or variation could mean:**

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

  
Name of Signatory Ketan Vyas  
Designation Chief Financial Officer



\*Funds Utilised includes Rs. 7.3 crore on account of issue related expenses